Biocon inks ‘Exclusive Agreement’ with Amylin Pharmaceuticals
Biocon has informed that the company has signed an exclusive agreement with Amylin Pharmaceuticals to jointly develop, commercialize and manufacture a novel Peptide Hybrid drug to be used for treatment of Diabetes.
According to an official communiqué, Amylin and Biocon would collaborate to develop the therapeutic potential of the compound and share development costs.
Under the arrangement, Amylin would provide expertise in peptide hormone development, particularly in the area of phybrid technology, as metabolic disease therapeutics.
However, Biocon would utilize its expertise to manufacture the compound and also leverage its experience in pre-clinical and clinical development of diabetes products.
A phybrid is a hybrid molecule that combines the pharmacological effects of two peptide hormones into a single molecular entity.